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Staphylococcus aureus causes a wide variety of diseases. Major virulence factors of this organism include
enterotoxins (SEs) that cause both food poisoning and toxic shock syndrome. Recently, a novel SE, tentatively
designated SEL, was identified in a pathogenicity island from a bovine mastitis isolate. The toxin had a
molecular weight of 26,000 and an isoelectric point of 8.5. Recombinant SEL shared many biological activities
with SEs, including superantigenicity, pyrogenicity, enhancement of endotoxin shock, and lethality in rabbits
when administered in subcutaneous miniosmotic pumps, but the protein lacked emetic activity. T cells bearing
the T-cell receptor  chain variable regions 5.1, 5.2, 6.7, 16, and 22 were significantly stimulated by recombi-
nant SEL.
Staphylococcus aureus is an important human and animal
pathogen, in part due to production of superantigen exotoxins
(SAgs). The spectrum of SAg-mediated illnesses ranges from
relatively benign food poisoning to life-threatening toxic shock
syndrome (TSS) (2, 7). The major secreted SAgs of S. aureus
include TSS toxin 1 (TSST-1) and enterotoxin (SE) serotypes
A to Q, excluding F.
Crystallographic studies of SAgs have shown that these mol-
ecules have similar three-dimensional structures (2, 7). The
toxins have a short N-terminal  helix that leads into a  barrel
structure known as the B domain or oligosaccharide-binding
(O/B) fold. The O/B fold is connected to a C-terminal wall of
 strands by a central diagonal  helix, forming domain A (
grasp fold). All SAgs have these features, but some differ
slightly in that they have small additional loops. The most
notable of these is a cysteine loop structure present in many of
the SEs and streptococcal pyrogenic exotoxin A (SPE A). This
loop is thought to be important for emetic activity in SEs (4).
Recently, SEs I, K, and Q, which lack the cysteine loop struc-
ture, have been identified; these toxins were shown to be su-
perantigenic, but the emetic activity was significantly reduced
in magnitude (SEI) or lacking (SEK and SEQ) (8–10). In
addition, TSST-1, which lacks cysteine residues, was shown to
be nonemetic (14).
This study was undertaken to purify and characterize a new
toxin, designated SEL, whose coding sequence had been de-
tected as an open reading frame in a pathogenicity island
(SaPIbov) from a bovine mastitis S. aureus isolate.
The gene sel was cloned from S. aureus TSS isolate MN Don.
PCR primers were chosen based on the sequences of SaPIbov
and SaPI4 (3). PCR primers including several hundred nucle-
otides at either end of sel were included in the original clone.
The PCR product was electrophoresed in 1% agarose, puri-
fied, and cloned into the TA vector pGEM T-easy (Promega,
Madison, Wis.), resulting in the plasmid pPMO031. This plas-
mid was transformed into Escherichia coli XL-1 Blue. The
entire sequence of sel was determined by automated sequenc-
ing (Biomedical Genomics and Advanced Genetic Analysis
Centers, University of Minnesota). To examine the biochemi-
cal and biological properties of SEL, a sel signal sequence
deletion mutation was cloned into pET28b by PCR amplifica-
tion of the pGEM T-easy insert. NcoI and BamHI restriction
sites were encoded in the primers for in-frame insertion of the
signal sequence deletion mutation into pET28b (the resultant
plasmid is referred to as pPMO032). The deleted signal pep-
tide of SEL was replaced with N-terminal methionine and
glycine residues. The N-terminal sequence of recombinant
SEL (rSEL) was determined experimentally to be MGNG
DVGPGP (single-letter designations) (Ben Madden, Mayo
Clinic, Rochester, Minn.). Transformation of pPMO032 into
E. coli XL-1 Blue was followed by purification of the plasmid
and verification of the construct by restriction digestion with
NcoI and BamHI. Subsequent to verification, the plasmid was
introduced into E. coli BL21(DE3) for expression by using the
ptac system.
The pET28b clone containing sel (pPMO032) in BL21(DE3)
was grown to early logarithmic phase in beef heart dialysate
(15) plus kanamycin (50 g/ml) at 37°C with shaking and then
induced with 200 M isopropyl thiogalactoside. After growth
overnight under the same conditions, the cultures were treated
with 4 volumes of absolute ethanol for 48 h to precipitate
toxins, and then preparative thin-layer isoelectric focusing (15)
was performed. Final purification was accomplished by using a
gel filtration column (Bio-Rad Laboratories, Hercules, Calif.)
* Corresponding author. Mailing address: Department of Microbi-
ology, University of Minnesota Medical School, Mayo Mail Code 196,
420 Delaware St. SE, Minneapolis, MN 55455. Phone: (612) 624-9471.
Fax: (612) 626-0623. E-mail: pats@lenti.med.umn.edu.
† Present address: Department of Environmental Engineering Sci-
ence, California Institute of Technology, Pasadena, CA 91125.
‡ Department of Microbiology, Moyne Institute of Preventive Med-
icine, University of Dublin, Trinity College, Dublin 2, Ireland.
2916
containing Sephadex G-75 (Sigma Chemical Company, St.
Louis, Mo.). Purity was verified by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis in which 10 g of rSEL
gave a homogeneous band of the appropriate molecular weight
(5). The protein concentration was assessed by using the Brad-
ford assay (Bio-Rad), and protein was stored in the lyophilized
state until used in biological and biochemical assays. The iso-
electric point (pI) was determined by measuring the pH of the
rSEL fraction eluted from the pH 7 to 9 isoelectric focusing
plate.
Rabbit splenocyte proliferation was used to assess the super-
antigenicity of rSEL (1).
American Dutch belted rabbits were given injections of toxin
in phosphate-buffered saline (PBS) at doses of 10, 1, and 0.1
g/kg of body weight intravenously, followed by a sublethal
dose of endotoxin (10 g/kg) to assess both pyrogenicity and
the ability to enhance susceptibility to endotoxin shock (13).
Six American Dutch belted rabbits were implanted with mini-
osmotic pumps containing 200 l (200 or 500 g) of either
TSST-1 or rSEL (11). Lethality of the toxins was assessed over
a period of 15 days. The stimulation profile of rSEL for human
T cells, with regard to the T-cell receptor  chain variable
region (TRBV), was determined by flow cytometry (9, 10). The
emetic capacity of rSEL compared to that of SEC1 was ana-
lyzed by a standard monkey feeding assay (14). Each toxin was
dissolved in flavored fruit punch (Lyons-Magnus, Clovis, Cal-
if.) and, using a sterile syringe, was fed to young adult pigtail
monkeys (Macaca nemestrina) weighing between 5 and 10 kg.
Prior to use in experiments, the animals were trained to accept
fluids willingly from a syringe so that physical restraint or
anesthesia was not needed. The minimal emetic dose for SEC1
in this assay was 0.1 to 1.0 g/kg.
The gene sel was cloned from S. aureus clinical isolate MN
Don. Concurrently sel was identified and sequenced from a
strain of S. aureus isolated from a bovine mastitis case (3). The
gene was shown to be part of an S. aureus pathogenicity island
in both strains (SaPI4 and SaPIbov, respectively). The amino
acid sequences predicted from the sel genes identified were
virtually identical, with a single amino acid change from me-
thionine to isoleucine (M195I) in the SEL from strain MN
Don.
Primary sequence analysis showed that SEL belongs in a new
subfamily of SEs (group V), along with the other recently
described novel SEs, SEI, -K, and -Q (7). Primary sequence
comparison with members of other previously described sub-
families also revealed several potentially important structural
elements. Like other recently described SAgs, SEL was more
similar to other SEs at the carboxyl terminus than at the amino
terminus, and the toxin contained residues known to be im-
portant in Zn2 coordination (6, 12). SEL contained no cys-
teine residues, and the region corresponding to the character-
istic cysteine loop in classical SEs was absent in this toxin.
The biochemical properties of rSEL are somewhat different
from those of previously described SEs. The putative mature
protein was about 20 amino acids shorter than the average SE,
though it was similar to SEK and -Q. The mature SEL se-
quence was 218 amino acids in length, with a predicted mo-
lecular weight of 25,219. The mature protein as purified from
the pET cloning and expression system had an observed pI of
8.5. This was similar to the predicted pI of 8.1 based on the
mature sequence including an N-terminal methionine and gly-
cine added to the expressed protein. The N-terminal 10 amino
acids of the purified recombinant toxin were MGNGDVG
PGP, as determined by protein sequencing.
The purified rSEL was active in in vitro and in vivo tests of
superantigenicity and TSS, respectively. rSEL was tested for
superantigenicity in a standard assay of rabbit splenocyte stim-
ulation (Fig. 1). Maximal stimulation of splenocyte prolifera-
tion was observed at a toxin concentration of 1.0 g/well, but
the protein was significantly mitogenic at doses as low as 108
g/well. An rSEL dose approximately 100-fold-lower than the
TSST-1 dose was required to induce significant lymphocyte
proliferation. Significant fever (0.5°C) was induced in three
rabbits per group 4 h after injection with rSEL at all three
concentrations tested (10, 1, and 0.1 g/kg). The toxin was
lethal at two of the three doses (10 and 1 g/kg), as tested in
the endotoxin enhancement model of TSS, with two of three
and three of three animals succumbing compared to none of
three at the 0.1-g/kg exotoxin dose (P  0.05 by Fischer’s
exact test when deaths of animals receiving 1 g of rSEL/kg
followed by endotoxin were compared to deaths of animals
receiving 0.1 g of exotoxin/kg followed by endotoxin). rSEL
was tested for lethality in a rabbit miniosmotic pump model of
TSS at doses of 200 and 500 g/rabbit over a period of 15 days.
The toxin was nonlethal at 200 g and lethal in one of three
rabbits at 500 g. This contrasts with TSST-1, which was lethal
for all three rabbits exposed to 200 g over the 15-day period.
rSEL was administered orally to 5 M. nemestrina monkeys at
doses of 6.5 (n  1), 10 (n  2), and 100 (n  2) g/kg. None
of the animals exhibited an emetic response or any other en-
teric symptoms characteristic of classical SEs. In contrast, 50
g of SEC1/kg induced emesis in two of two animals.
The TRBV profile of human T cells stimulated with rSEL
was examined by flow cytometry with monoclonal antibodies
directed against the repertoire of human TRBV subsets. It was
observed that T cells bearing TRBV 5.1, 5.2, 6.7, 16, and 22
were preferentially activated by the toxin (Fig. 2). T cells with
TRBV 5.1, 5.2, and 16 were statistically highly significantly
stimulated (P  0.005), and T cells with TRBV 5.1 had the
highest level of proliferation (18% of T cells, averaged over
five study subjects tested), implying a likely biological signifi-
cance for this TRBV subset. We observed that primarily CD4
T cells but also CD8 T-cell populations were expanded in
some cases. TRBV 16- and 23-bearing T cells were also en-
hanced in all five study subjects, but not in a statistically sig-
nificant manner. In these cases, the percent reduction of CD8
T cells bearing these TRBV chains was responsible for the lack
of statistical significance. The rise in TRBV 16 and 23 CD4 T
cells in response to rSEL was significant (P  0.05). The
proliferation of cells bearing TRBV 7 in samples stimulated
with rSEL was variable; it was enhanced twofold in one study
subject’s lymphocytes compared to that following stimulation
with anti-CD3 antibodies. Samples from only three of five
study subjects contained increased levels of this T-cell type,
however. The populations of T cells bearing certain TRBV
subsets were reduced, consistent with the effect of SAgs. Ex-
amples of this effect include TRBV 2, 8, 13.1, and 14. These
apparent reductions in certain subsets of T cells do not result
from apoptosis or other loss of those subsets but rather reflect
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the significant overrepresentation of the stimulated T-cell sub-
sets relative to those that are not stimulated.
The data presented in this work indicate that a novel en-
terotoxin gene, sel, was present, together with two different sec
molecular variants, in pathogenicity islands SaPIbov and SaPI4
(3). rSEL had biological activities, excluding emesis, similar to
those of previously described SEs and other SAgs in general.
Analysis of the sequence of sel showed that the gene and its
encoded protein fit into a new subfamily of SEs, along with the
recently described SEI, SEK, and SEQ (7).
rSEL was superantigenic and pyrogenic and enhanced the
toxic effects of endotoxin in a rabbit model. It was only weakly
lethal in a miniosmotic pump model of TSS in rabbits. This
reduced effectiveness in the miniosmotic pump model may be
caused by the instability of the purified protein in vivo or
intrinsic lack of activity over the 15-day time period. However,
the toxin was fully capable of enhancing susceptibility to en-
dotoxin in rabbits in a 24-h assay. rSEL was a potent T-cell
SAg, capable of stimulating high levels of both CD4 and
CD8 T-cell proliferation. The activity was comparable to that
FIG. 1. Rabbit splenocyte mitogenicity of rSEL compared to that of TSST-1. Splenocytes (2 	 105/well) in quadruplicate wells of a microtiter
plate were stimulated for 3 days with the indicated amounts of rSEL or TSST-1, and then 1 Ci of [3H]thymidine was added to each well. Cells
were then reincubated for another day, and DNA was harvested onto glass fiber filters. Counts per minute were determined by scintillation
counting. Negative-control wells (neg control) contained splenocytes only.
FIG. 2. TRBV profile of rSEL. Peripheral blood mononuclear cells from five study subjects were stimulated with either anti-CD3 (white bars),
which stimulates all T cells, or rSEL (black bars), which selectively stimulates T cells dependent on the TRBVs. Cells were stained with monoclonal
antibodies against listed TRBVs, and the results were evaluated by flow cytometry. The percentages of T cells expressing the listed TRBVs are
shown. Results from all five study subjects are reflected in each case, except for those for TRBV 6.7, which are the averages of four of five study
subjects (results for the fifth study subject were not obtained). P values were determined by using the paired Student t test (, P  0.046; , P 
0.009; , P  0.003). Error bars represent the standard errors for each data set.
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of other SAgs in this regard. SEL was also a potent inducer of
fever in rabbits, with a minimum pyrogenic dose consistent
with those for other SAgs.
Interestingly, at a dose of 100 g/kg, rSEL did not cause
emetic responses in monkeys. This dose of toxin is 100- to
1,000-fold in excess of the amount of SEC1 required to cause
emesis in this model (14). It is possible that this lack of emetic
activity resulted in part from an inability to form a disulfide
bond characteristic of the classical SEs such as SEA to SEE.
Those SAgs that lack the loop previously have been shown to
be only weakly emetic or nonemetic (8–10). In addition, Hovde
and colleagues (4) showed that by changing the cysteine resi-
dues in SEC3 to alanines the emetic activity of the molecule
was lost. It is possible that the ability to form disulfide bonds
constrains other aspects of the SE structure such that the
molecules retain emetic activity. From our studies it was also
clearly shown that emetic activity was separable from superan-
tigenicity, in that rSEL was not emetic yet the toxin was su-
perantigenic. This is consistent with previous data obtained in
studies comparing the biological activities of SPE A, TSST-1,
and SEC1 (14).
rSEL stimulated T cells in a manner similar to that of pre-
viously described SAgs, but it had a TRBV profile distinct from
those previously observed. As indicated above we have shown
that T cells bearing TRBV 5.1, 5.2, 6.7, 16, and 22 are signif-
icantly stimulated by rSEL in vitro.
Finally, it is noteworthy that rSEL has the strongest homol-
ogy with other SEs in the C-terminal region, where major
histocompatibility complex class II molecules may be bound by
certain SAgs in a high-affinity site and which contains a Zn2
molecule (6, 7). These residues, important for Zn2 binding in
SEA, -H, and -K and SPE C, are present in the same positions
relative to one another in rSEL (His17, His209, and Asp211).
We do not know if Zn2 is present in rSEL, but clearly the
positions of these coordination residues suggest that rSEL has
this high-affinity site.
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